304 related articles for article (PubMed ID: 26319441)
21. Impact of a Brief Educational Intervention on Glaucoma Persistence: A Randomized Controlled Clinical Trial.
Djafari F; Lesk MR; Giguère CÉ; Siam G; Freeman EE
Ophthalmic Epidemiol; 2015; 22(6):380-6. PubMed ID: 26653260
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma.
Friedman DS; Okeke CO; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Quigley HA
Ophthalmology; 2009 Jun; 116(6):1097-105. PubMed ID: 19376591
[TBL] [Abstract][Full Text] [Related]
23. Persistence and adherence with topical glaucoma therapy.
Nordstrom BL; Friedman DS; Mozaffari E; Quigley HA; Walker AM
Am J Ophthalmol; 2005 Oct; 140(4):598-606. PubMed ID: 16226511
[TBL] [Abstract][Full Text] [Related]
24. Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project.
McCarty CA; Mukesh BN; Kitchner TE; Hubbard WC; Wilke RA; Burmester JK; Patchett RB
J Glaucoma; 2008 Aug; 17(5):372-7. PubMed ID: 18703947
[TBL] [Abstract][Full Text] [Related]
25. Measurement of adherence to brimonidine therapy for glaucoma using electronic monitoring.
Hermann MM; Bron AM; Creuzot-Garcher CP; Diestelhorst M
J Glaucoma; 2011 Oct; 20(8):502-8. PubMed ID: 20852438
[TBL] [Abstract][Full Text] [Related]
26. Adherence and persistence with glaucoma therapy.
Schwartz GF; Quigley HA
Surv Ophthalmol; 2008 Nov; 53 Suppl1():S57-68. PubMed ID: 19038625
[TBL] [Abstract][Full Text] [Related]
27. Psychosocial Predictors of Glaucoma Medication Adherence Among the Support, Educate, Empower (SEE) Personalized Glaucoma Coaching Pilot Study Participants.
Salman M; Andrews C; Heisler M; Darnley-Fisch D; Newman-Casey PA
Am J Ophthalmol; 2020 Aug; 216():207-218. PubMed ID: 32087145
[TBL] [Abstract][Full Text] [Related]
28. The relationship between sociodemographic factors and persistence with topical glaucoma medications.
Leung VC; Jin YP; Hatch W; Mammo Z; Trope GE; Buys YM; Macrae WG
J Glaucoma; 2015 Jan; 24(1):69-76. PubMed ID: 25055210
[TBL] [Abstract][Full Text] [Related]
29. Three and five year changes in intraocular pressures after clear corneal phacoemulsification in open angle glaucoma patients, glaucoma suspects, and normal patients.
Shingleton BJ; Pasternack JJ; Hung JW; O'Donoghue MW
J Glaucoma; 2006 Dec; 15(6):494-8. PubMed ID: 17106361
[TBL] [Abstract][Full Text] [Related]
30. Systemic antihypertensive medication and incident open-angle glaucoma.
Müskens RP; de Voogd S; Wolfs RC; Witteman JC; Hofman A; de Jong PT; Stricker BH; Jansonius NM
Ophthalmology; 2007 Dec; 114(12):2221-6. PubMed ID: 17568677
[TBL] [Abstract][Full Text] [Related]
31. The United Kingdom Glaucoma Treatment Study: a multicenter, randomized, placebo-controlled clinical trial: design and methodology.
Garway-Heath DF; Lascaratos G; Bunce C; Crabb DP; Russell RA; Shah A;
Ophthalmology; 2013 Jan; 120(1):68-76. PubMed ID: 22986112
[TBL] [Abstract][Full Text] [Related]
32. Patterns of care for open-angle glaucoma in managed care.
Fremont AM; Lee PP; Mangione CM; Kapur K; Adams JL; Wickstrom SL; Escarce JJ
Arch Ophthalmol; 2003 Jun; 121(6):777-83. PubMed ID: 12796247
[TBL] [Abstract][Full Text] [Related]
33. Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization.
Trese MGJ; Lewis AW; Blachley TS; Stein JD; Moroi SE
J Ocul Pharmacol Ther; 2017 Oct; 33(8):591-597. PubMed ID: 28854348
[TBL] [Abstract][Full Text] [Related]
34. Glaucoma severity and medication adherence in a county hospital population.
Ung C; Zhang E; Alfaro T; Murakami Y; Zhang M; Seider MI; Lin SC; Singh K
Ophthalmology; 2013 Jun; 120(6):1150-7. PubMed ID: 23453512
[TBL] [Abstract][Full Text] [Related]
35. Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring.
Hermann MM; Papaconstantinou D; Muether PS; Georgopoulos G; Diestelhorst M
Acta Ophthalmol; 2011 Jun; 89(4):e300-5. PubMed ID: 21106046
[TBL] [Abstract][Full Text] [Related]
36. Predicting Adherence With the Glaucoma Treatment Compliance Assessment Tool.
Sanchez FG; Mansberger SL; Newman-Casey PA
J Glaucoma; 2020 Nov; 29(11):1017-1024. PubMed ID: 32740508
[TBL] [Abstract][Full Text] [Related]
37. Glaucoma management among individuals enrolled in a single comprehensive insurance plan.
Friedman DS; Nordstrom B; Mozaffari E; Quigley HA
Ophthalmology; 2005 Sep; 112(9):1500-4. PubMed ID: 16039717
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcomes of prostaglandin analog versus timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe.
Holló G; Thelen U; Teus MA; Quaranta L; Ferkova S; Babić N; Misiuk-Hojlo M; Mikropoulos DG; Kaluzny BJ; Kozobolis V; Januleviciene I; Kóthy P; Camara C; Russo A; Krzyzanowska-Berkowska P; Cieślińska I; Stewart JA; Kristoffersen MS; Nelson LA; Stewart WC
J Ocul Pharmacol Ther; 2011 Oct; 27(5):493-8. PubMed ID: 21790326
[TBL] [Abstract][Full Text] [Related]
39. Glaucoma treatment adherence at a United Kingdom general practice.
Tse AP; Shah M; Jamal N; Shaikh A
Eye (Lond); 2016 Aug; 30(8):1118-22. PubMed ID: 27256302
[TBL] [Abstract][Full Text] [Related]
40. Treatment adherence in newly diagnosed type 2 diabetes: patient characteristics and long-term impact of adherence on inpatient care utilization.
Sun P; Lian J
Postgrad Med; 2016 May; 128(4):338-45. PubMed ID: 26849064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
